Edgar G. Engleman, M.D.
Dr. Engleman is a founding member of Vivo Ventures, LLC (formerly
Dr. Engleman is Professor of Pathology and Medicine at Stanford
University School of Medicine, where he oversees the Stanford Blood
Center and his own immunology research group. An editor of numerous
scientific journals and the inventor of multiple patented technologies,
Dr. Engleman has authored more than 250 publications in medical and
scientific journals and has trained more than 200 graduate students and
He has co-founded a number of biopharmaceutical companies including
Cetus Immune, Genelabs, National Medical Audit and Dendreon. He is the
lead inventor of the technology underlying Provenge, Dendreon's cancer
vaccine, which was shown to extend life for patients with metastatic
prostate cancer with remarkably few side effects. Provenge is the first
active immunotherapeutic agent to be approved by the FDA (in 2010).
Dr. Engleman currently serves on the boards of several private
biotechnology companies. He received his B.A. from Harvard University
and his M.D. from Columbia University School of Medicine.